Sonoma Pharmaceuticals Highlights Safety Advantages of its Microcyn Products in Light of Growing Concerns of Benzene in Many Other Topicals
- None.
- None.
Insights
The revelation of potential carcinogenic effects due to benzoyl peroxide in dermatology products presents a significant shift in the consumer healthcare market. The focus on Sonoma Pharmaceuticals' Microcyn technology, which leverages hypochlorous acid (HOCl), could position the company favorably as a provider of safer alternatives. HOCl is a compound with known antimicrobial properties and a favorable safety profile, which could see increased demand in light of these safety concerns.
From a medical research perspective, the efficacy of HOCl in managing skin conditions, coupled with its safety advantages, positions Sonoma's products as potentially preferable options in wound care and dermatological treatments. This could lead to an expansion in market share for Sonoma, especially if the FDA takes regulatory action against benzoyl peroxide-containing products. However, it's important to monitor any further clinical evidence supporting the safety and effectiveness of Microcyn technology to fully assess its market potential.
The healthcare industry often experiences shifts in product demand due to safety concerns. Sonoma Pharmaceuticals' emphasis on the safety of their Microcyn technology could resonate well with consumers and healthcare providers. As an FDA-regulated 510(k) medical device, these products may see an uptick in sales, especially within the dermatological sector that is actively seeking alternatives to benzoyl peroxide.
Furthermore, the company's proactive communication strategy in highlighting the safety of their products could enhance their brand reputation and trust with consumers. While this news could positively impact Sonoma's stock in the short term, the long-term effects will depend on the company's ability to capitalize on this opportunity and whether competitors will introduce similar safe alternatives. It's also vital to consider the potential for increased research and development costs as Sonoma might aim to expand its product range to seize this market opportunity.
The concerns raised by Valisure's testing of benzoyl peroxide products underscore the importance of risk management in the pharmaceutical and healthcare industries. For Sonoma Pharmaceuticals, the focus on non-benzoyl peroxide products could serve as a risk mitigation strategy, potentially shielding the company from the fallout of any FDA recalls or negative consumer sentiment towards benzoyl peroxide.
However, it's important for Sonoma to ensure that they do not face similar challenges with their own products. Continuous investment in product testing and adherence to regulatory compliance is essential to maintain their position as a safe alternative. Additionally, the company must be prepared to manage supply chain demands and potential scaling of production in response to increased market demand for Microcyn technology products.
BOULDER, CO / ACCESSWIRE / March 27, 2024 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care and dermatological conditions, highlights the safety advantages of its Microcyn technology products in response to concerns related to benzoyl peroxide, a common ingredient in dermatology products.
Recently, there have been concerns that popular dermatology products can form benzene, a known carcinogen. A citizen petition by Valisure, LLC, an independent testing laboratory for pharmaceuticals, requested an FDA recall of certain over-the-counter and prescription dermatology products containing benzoyl peroxide. Testing by Valisure showed that benzoyl peroxide in dermatology products from major brands can form benzene, a known human carcinogen, at unacceptably high levels. Previous testing by Valisure has found unacceptably high levels of benzene in common hand sanitizers, as well as in after-sun products.
Sonoma's Microcyn products contain hypochlorous acid, a naturally-occurring compound found in the human body. Our patented Microcyn technology is clinically proven to safely remove microorganisms, without drying the skin or harming healthy tissue. Our products also manage pain and itch from minor skin irritations, lacerations, abrasions and minor burns, including sunburns. Unlike many over-the-counter dermatology products, Sonoma's products are regulated by the FDA as 510(k) medical devices. Sonoma has never used benzoyl peroxide in any of its products.
"We understand that consumers are seeking safe and effective products, particularly now when there are so many concerns about dangerous ingredients in dermatology and other topical products," said Amy Trombly, CEO of Sonoma Pharmaceuticals. "For over 20 years, we have developed Microcyn technology products that prioritize the health of patients and at-home users, so that consumers do not have to choose between effectiveness and safe ingredients."
For more information, or to order any of Sonoma's Microcyn technology products, visit https://otc.sonomapharma.com for consumers or https://pro.sonomapharma.com/ for healthcare professionals, or contact our customer service department at 720-452-9690 or customerservice@sonomapharma.com.
About Sonoma Pharmaceuticals, Inc.
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care and dermatological conditions. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin. Sonoma's products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company's principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the "company"). These forward-looking statements are identified by the use of words such as "continue," "develop," "anticipate," "expect" and "expand," among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company's products will not be as large as expected, the company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company's cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.
SOURCE: Sonoma Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
What is Sonoma Pharmaceuticals' ticker symbol?
What safety advantages do Sonoma's Microcyn technology products offer over benzoyl peroxide-containing dermatology products?
What recent concerns have prompted a citizen petition for an FDA recall?
What compound is the basis of Sonoma's Microcyn technology products?
Has Sonoma Pharmaceuticals ever used benzoyl peroxide in its products?
